Grace Therapeutics (GRCE) KOL Event summary

Introduction and agenda

• Event focused on GTx-104, a novel injectable nimodipine for aneurysmal subarachnoid hemorrhage (aSAH), with forward-looking statements and a Q&A session planned.

• Agenda included disease overview, challenges with current oral nimodipine, and market opportunity for GTx-104.

KOL background and credentials

• Dr. Abhishek Ray: neurosurgeon at University Hospitals, Case Western Reserve, experienced in cerebrovascular surgery and clinical trials.

• Dr. Andrew Webb: neurocritical care pharmacist at MGH, expert in medication delivery, formulary decisions, and acute brain injury.

Market insights and analysis

• aSAH is a severe, often fatal condition with high pre-hospital and in-hospital mortality, especially in older women.

• Oral nimodipine is the only FDA-approved drug for aSAH but has significant limitations in critically ill patients.

• Up to 50% of patients may not tolerate oral nimodipine during their hospital course due to dysphagia or complications.

• IV nimodipine could address unmet needs, especially for patients unable to take oral medications.